Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer

Inclusion Criteria:

Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), including any of the following histologic subtypes:

Squamous cell carcinoma
Adenocarcinoma
Large cell undifferentiated carcinoma
Stage II or IIIA disease
Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral Computerized Axial Tomography (CT) scan
No tumor involving the superior sulcus (e.g., Pancoast tumor)
Karnofsky performance status 70-100%
Absolute neutrophil count ≥ 1,500/mm^3
Platelet count ≥ 100,000/mm^3
Creatinine ≤ 2 mg/dL
Bilirubin < 2 mg/dL
Aspartate aminotransferase (AST) < 3 times upper limit of normal

Exclusion Criteria:

Pregnant or nursing

No nursing during and for ≥ 4 weeks after completion of study treatment
Positive pregnancy test
Fertile female patients must use 2 effective methods of contraception 4 weeks before, during, and for 4 weeks after completion of study treatment
Fertile male patients must use effective barrier contraception during and for 4 weeks after completion of study treatment
Blood, sperm, or ova donation during study treatment
Post obstructive pneumonia
Other serious infection or medical illness that would preclude study participation
Other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other malignancy that is unlikely to affect survival for the next 3 years
Less than 5 years since prior resection of lung disease
Prior systemic chemotherapy or radiotherapy for non-small cell lung cancer (NSCLC)
Other concurrent chemotherapy or radiotherapy
Concurrent hormonal therapy or immunotherapy
Other concurrent anticancer therapy
Other concurrent investigational agents
Concurrent participation in another clinical study